News
Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting
SAN DIEGO, Oct. 1, 2021 /PRNewswire/ — Poseida Therapeutics, Inc. (Nadsaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it will give two virtual poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C., and virtually November 10-14, 2021.
Details on the two poster presentations are as follows. The full abstracts will be made available on the SITC website on November 9, 2021.
Title: Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control
Presenter: Hubert Tseng, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 147
Title: P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor
Presenter: Yan Zhang, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 123